

The Use of High-Throughput Technologies to Investigate Vascular Inflammation and Atherosclerosis

Yvonne Döring, Heidi Noels, Christian Weber

Abstract—The greatest challenge of scientific research is to understand the causes and consequences of disease. In recent years, great efforts have been devoted to unraveling the basic mechanisms of atherosclerosis (the underlying pathology of cardiovascular disease), which remains a major cause of morbidity and mortality worldwide. Because of the complex and multifactorial pathophysiology of cardiovascular disease, different research techniques have increasingly been combined to unravel genetic aspects, molecular pathways, and cellular functions involved in atherogenesis, vascular inflammation, and dyslipidemia to gain a multifaceted picture addressing this complexity. Thanks to the rapid evolution of high-throughput technologies, we are now able to generate large-scale data on the DNA, RNA, and protein levels. With the help of sophisticated computational tools, these data sets are integrated to enhance information extraction and are being increasingly used in a systems biology approach to model biological processes as interconnected and regulated networks. This review exemplifies the use of high-throughput technologies—such as genomics, transcriptomics, proteomics, and epigenomics—and systems biology to explore pathomechanisms of vascular inflammation and atherosclerosis. (*Arterioscler Thromb Vasc Biol.* 2012;32:182-195.)

Key Words: atherosclerosis ■ coronary artery disease ■ vascular biology ■ high-throughput ■ systems biology

As the underlying pathology of cardiovascular disease, atherosclerosis entails a chronic inflammation of the vascular wall, which is initiated by vascular structural alterations and the subendothelial accumulation of low-density lipoprotein (LDL). On oxidation, oxidized LDL elicits the activation of endothelial cells (ECs), mediating leukocyte recruitment. Intimal neutrophils, T cells, and monocyte-derived macrophages contribute to sustained inflammation, causing early fatty streak lesions to progress into advanced fibroatheromatous plaques, which, on gradual thinning of the protective smooth muscle cell (SMC) cap, transform into rupture-prone lesions.¹ Although atherosclerosis starts in childhood, it is mostly diagnosed only at a late stage. Optimized treatment requires the understanding of the disease-associated mechanisms. However, atherosclerosis is a multifactorial disease and results from an intricate interplay of multiple genes, signaling pathways, cells, and tissues. Also, many environmental factors, such as hyperlipidemia and hypertension, have been identified as risk factors for atherosclerosis, which further increases the complexity of the disease. This review discusses the use of high-throughput approaches to study atherosclerosis, and also briefly addresses cerebrovascular diseases (focusing on stroke) and peripheral artery disease (PAD). Although the latter is a direct consequence of atherosclerosis, cerebrovascular dis-

eases comprise a variety of disorders (eg, vascular dementia or subarachnoid hemorrhage), with stroke being the most numerous. About 80% of strokes are ischemic, and atherosclerosis, but cardioembolism mostly triggered by atrial fibrillation—and small-vessel disease are also very common causes.^{2,3} The multifaceted pathomechanisms underlying all these diseases necessitate a holistic study approach. Therefore, in vitro experiments, which lack the complex organization of an organism, need to be combined with clinical and animal studies. In atherosclerosis research and many other disorders, mice are the gold standard, and although they do not meet all criteria of human diseases, they offer great advantages because of the relatively low cost, easy access, high fertility, and availability of numerous biological tools, including genetic modifications.⁴⁻⁶ However, not only mice but also other animals, such as rabbits, hamsters, pigs, and dogs, have been used to study atherosclerosis and vascular inflammation.^{7,8}

Importantly, animal models provide the opportunity to apply high-throughput technologies, which enable the generation of large-scale data on DNA, RNA, and protein levels, to a broad variety and high number of cell and tissue samples, including those that are not available from humans (eg, genetically modified background). Furthermore, computational tools have been developed to integrate all these

Received on: October 31, 2011; final version accepted on: December 5, 2011.

From the Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Munich, Germany (Y.D., C.W.); Institute for Molecular Cardiovascular Research, Rheinisch-Westfälische Technische Hochschule Aachen University, University Clinic Aachen, Aachen, Germany (H.N.); Munich Heart Alliance, Munich, Germany (C.W.); Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, the Netherlands (C.W.).

Dr Döring and Dr Noels contributed equally to this work.

Correspondence to Christian Weber, Institut für Prophylaxe und Epidemiologie der Kreislaufkrankheiten, Klinikum der Universität München, Pettenkoferstrasse 9, 80336 München, Germany. E-mail christian.weber@med.uni-muenchen.de

© 2012 American Heart Association, Inc.

Arterioscler Thromb Vasc Biol is available at <http://atvb.ahajournals.org>

DOI: 10.1161/ATVBAHA.111.232686

“omics”-based data for improved information extraction. In addition, biological processes are increasingly being approached from a systems biology point of view, aiming to model them as interconnected networks, and this has revealed information on disease-associated mechanisms that would never have been discovered with a classical approach.⁹

This review outlines the use of high-throughput technologies in the research field of vascular inflammation and cardiovascular disease. The widespread application of genomics, transcriptomics, and proteomics in biomedical research makes it impossible to address these techniques in a detailed way. Instead, we discuss selected studies to exemplify the context of their usage, their advantage versus classical small-scale approaches, and their current limitations. In addition, we address the rising field of epigenomics in cardiovascular disease.

We sincerely apologize to all scientists whose important contributions to the field could not be cited because of space constraints.

Genomics

Genomics involves the genome-wide sequencing and annotation of an organism's DNA, including the identification of open reading frames and regulatory elements, such as transcription factor binding sites. The sequencing of the complete human genome and the rise of high-throughput technologies as DNA microarray multiplex genotyping, enabling genome- and population-wide screens of single-nucleotide polymorphisms (SNPs) or copy number variations, has triggered an explosion of genome-wide association studies (GWASs), aiming to identify disease-associated genetic loci using disease quantitative trait locus (QTL) mapping.¹⁰ Furthermore, metaanalyses of multiple GWAS data sets have considerably increased the power to detect genetic disease associations.¹⁰ In this way, many susceptibility loci have been identified for coronary artery disease (CAD) and myocardial infarction,^{1,11–13} as discussed in more detail in another review of this series. Also, chromosomal loci associated with stroke, PAD, and serum lipid levels have been revealed.^{13–17} However, many of the identified loci still require independent replication to avoid false-positive results.^{18–20} Studies examining PAD-associated chromosomal loci to unravel disease mechanisms are scarce.^{21–23} Notably, several approaches have been made to open up the way for successful GWAS in addressing PAD with the help of electronic medical records, including the storage of DNA and plasma samples, as well as demographic data and laboratory values.^{24,25}

Despite the recent explosion of GWAS-generated disease-associated susceptibility loci, single genetic loci or even their combination can only explain a small fraction of the risk for multifactorial diseases, such as atherosclerosis.⁹ In addition, GWASs have the considerable drawback that the identified susceptibility loci mostly do not reveal direct information on disease genes or affected pathways, which is crucial for therapeutic drug discovery. Therefore, human GWAS-generated susceptibility loci have been combined with corresponding mouse disease QTLs in a cross-species comparative genomics approach to narrow down susceptibility intervals.²⁶ In addition, complementation of clinical trait QTL data with

transcriptomics^{17,27,28} and expression QTL (eQTL) mapping^{29–32}, which aims to map chromosomal loci that are strongly associated with RNA expression (expression SNPs), can considerably facilitate candidate disease gene identification. For example, combination of GWAS and mouse clinical QTLs identified LSq1, a locus on mouse chromosome 7, to be responsible for the infarct volume of ischemic stroke in mice, and the risk allele of SNP rs4783244 is significantly associated with decreased plasma adiponectin levels, pointing to an increased risk of ischemic stroke.^{33,34} Furthermore, a genome-wide SNP scan and atherosclerosis QTL mapping in intercrosses of mouse strains with different atherosclerosis-susceptibility were combined with macrophage gene expression profiling and transcription factor binding site analysis to reveal genes and promoter elements associated with atherosclerosis susceptibility. The genes *Wbscr* and *Aps*, which were differentially expressed in macrophages from mice with high versus low atherosclerosis susceptibility, mapped close to a specific atherosclerosis QTL on chromosome 5, indicating these genes as potential candidates influencing atherosclerosis risk.³⁵ In a comparable approach, QTL mapping for atherosclerotic plaque size in a segregating mouse population with variable atherosclerosis susceptibility was combined with transcriptome analysis of liver and adipose tissue and subsequent eQTL mapping, allowing a prioritization of the atherosclerosis QTL-associated candidate genes based on colocalization with *cis*-acting eQTLs.²⁹ Similarly, eQTLs affecting gene expression in human liver were screened for correlation with CAD-associated QTLs identified by GWASs, revealing the genes *SORT1*, *PSRC1*, *CELSR2*, and *SYPL2* on chromosome 1p13.3 as potential candidates for CAD development. Transcriptional analysis of these genes in the liver of a segregating mouse population with varying atherosclerosis risk furthermore indicated expression levels of *Sort1*, *Psrc1* and *Celsr2*, but not *Sypl2*, to be significantly associated with plasma LDL cholesterol levels, a risk factor for CAD. Combination of genotypic and transcriptomic data enabled the modeling of a genome-wide gene network for both human and mouse and revealed the 3 genes to colocalize in a species-conserved subnetwork causally associated with cholesterol levels and atherosclerosis.³¹

The combination of clinical trait QTL mapping with expression profiling or eQTL mapping in a network-based framework is called systems genetics or integrative genetics, and it has also been successfully applied to identify genes and pathways underlying other complex diseases, such as obesity.^{36,37}

Network modeling is further discussed below, but a more comprehensive application of comparative genomics is outlined in a recent review.²⁶ Whether genetic screening will also be useful beyond cardiovascular disease gene identification (eg, for disease classification, outcome prediction, or therapy guidance) remains unclear.^{17,38,39}

Transcriptomics

Transcriptomics entails the genome-wide study of RNA expression, mostly through microarray analysis. It is a widely applied technique for studying mechanisms underlying diseases, and it has also extensively been used to study expression profiles of atherosclerotic-prone or atherosclerotic ves-

sels,⁴⁰ predominantly in human^{41–43} and mouse,^{44–46} but also in rat,⁴⁷ monkey,⁴⁸ and pig.⁴⁹ Macrodissection^{50–53} and laser-capture microdissection^{54–59} have furthermore enabled scientists to isolate and analyze specific subregions within atherosclerotic vessels or lesions, such as, eg, plaque area versus media and adventitia,⁵⁵ fibrous cap,^{50,51} lesion shoulder,⁵⁶ or adventitial aortic tertiary lymphoid organs.⁵⁷ In addition, these methods have allowed the enriched isolation of particular cell types, such as ECs^{49,53,58} or macrophages,⁵⁹ for subsequent genome-wide expression profiling, enhancing our understanding of cell type-specific functions in atherogenesis. Given that metabolic disorders, such as dyslipidemia, obesity, and diabetes, are risk factors for CAD, it is not surprising that also transcriptome analysis of organs relevant to energy metabolism has increased our insight into molecular processes associated with the presence or risk of CAD, as shown for liver^{60,61} and fat.^{30,32,62} For example, using expression profiles from human atherosclerotic arterial wall, carotid stenosis tissue and visceral fat, an atherosclerosis-associated set of genes was identified, which was linked with the transendothelial leukocyte migration pathway and with the transcriptional cofactor LDB2 as a potential hierarchical regulator. Associated expression SNPs of this gene set showed an increased association with CAD.⁶² In addition, integration of genotype, liver and adipose tissue gene expression profiles and aortic lesion size in a segregating mouse population identified 292 genes as potentially causal for aortic lesions. This causality was confirmed for *C3ar1* in a mouse knockout study, and the candidate causal genes, especially those from adipose tissue, were shown to strongly overlap with a plaque progression signature derived from transcriptional profiling of atherosclerotic aortic arches from 2 mouse models.³² Interestingly, also expression profiles of peripheral blood cells, crucial inflammatory mediators and key players in atherosclerotic lesions, have been shown to correlate with the occurrence and extent of CAD,^{63–65} and a gene expression-based blood test was recently developed to measure obstructive CAD in nondiabetic patients.⁶⁶ And although in vitro transcriptome studies fail to provide information on complex interactions between cells, organs and environment, they also have considerably contributed to our understanding of atherosclerosis-associated signaling pathways and biological processes in diverse cell types, as ECs,⁵³ SMCs⁶⁷ and monocytes.⁶⁸ For example, microarray analysis revealed an upregulation of *Wnt2* and *Wnt4* in platelet-derived growth factor–BB–induced, proliferating vascular SMCs (VSMCs) compared with unstimulated, resting VSMCs, and further in vitro studies showed *Wnt4* to trigger VSMC proliferation through Frizzled 1. The role of *Wnt4* in VSMC proliferation was confirmed in a *Wnt4*-deficient mouse model, demonstrating a significantly reduced intimal thickening and VSMC proliferation after carotid artery ligation.⁶⁷ In a similar approach, transcriptional profiling of human aortic ECs with knockdown of microRNA10a, which was found to be downregulated in the endothelium of atherosclerosis-susceptible regions of the aortic arch in swine, revealed nuclear factor- κ B–mediated inflammation as a key upregulated process. This could be confirmed in swine aortic arch ECs,⁵³ validating in vitro experiments as a useful

approach to gain insight into disease-related mechanisms. In addition, in vitro studies can provide first line indications of cellular responses to drugs. As such, transcriptional analysis of human ECs, SMCs, and hepatocarcinoma cells treated with orvastatin or pitavastatin showed statins to affect genes involved in coagulation, cell growth, and vascular constriction, providing insight into statins' cellular effects.⁶⁹

Finally, profiling of microRNAs, which are major regulators of mRNA expression, can also offer insights in atherosclerosis-related mechanisms, and has been performed on injured vascular walls,⁷⁰ plasma,⁷¹ blood,⁶⁵ and vascular cell types.⁵³ For instance, Fichtlscherer et al detected a significant reduction in the plasma concentration of vascular and inflammatory cell-derived microRNAs in patients with CAD, whereas cardiac muscle-microRNAs showed an increased trend.⁷¹ Whether specific microRNAs could also be used as biomarkers to predict the course of disease or classification remains to be further examined.

In the context of cerebrovascular disease and stroke, transcriptomic analysis was mainly set up to gain insight in the blood transcriptome after injury. Stroke-associated gene expression changes, for example, may be reflected within this transcriptome and therefore mediate cerebral inflammatory changes. In addition, animal models comparing changes in gene expression in cerebral tissue revealed an important role for blood microRNAs, which have also gained interest as biomarkers for brain injury.^{72,73} As an example, microRNA-124 has recently been described as biomarker for cerebral infarction.^{74,75} Another study explored the transcriptomic profiling of cellular pathways being regulated after an in vivo transient cerebral ischemic stroke in mice mediated in the presence and absence of glutathione peroxidase 1. Glutathione peroxidase 1 is an enzyme that is important in reduction of oxidative stress, and its lack has been implicated in neurodegenerative disorders and stroke. Here, the authors were able to show that glutathione peroxidase 1 plays a crucial role in the protection against oxidative stress and inflammation during ischemia-reperfusion injury.⁷⁶

Regarding PAD, Zhao et al performed a microarray analysis of 30 femoral artery samples identifying, for example, MAP4K4 as being differentially upregulated in intermediate and advanced lesions. Surprisingly, many of the differentially regulated genes in this study have not been reported to be related to atherosclerosis before.⁷⁷ A similar approach was used by Evans et al, who classified 335 genes as differentially regulated between normal and diseased arteries. Moreover, they were able to acknowledge a gene expression signature for PAD and an associated diabetic phenotype in PAD.⁷⁸

Proteomics

Dynamic proteins are key regulators of biological functions. The total protein complement of an organism and its genome is called proteome. Methods trying to unravel protein structure, expression, modification, localization and protein-protein interactions are referred to as proteomics.^{79–81} Most important proteomic methods comprise 2-dimensional gel electrophoresis (2-DE) or 2D differential in-gel electrophoresis, which is an improved 2-DE, including the fluorescent labeling of the different protein suspensions investigated. Moreover, gel-liquid chromatography–tandem mass spec-

trometry and shotgun (gel-free) proteomics are used to explore proteomic functions. Using gel-based proteomics, proteins are first separated by 1- or 2-DE before enzymatic digestion and mass spectrometry (MS) analysis. Shotgun proteomics uses the digested protein mixture directly without the need for gel separation.^{79,82}

In the past decade, several attempts were made to exploit the VSMC^{83–85} and EC^{86–88} proteomes in different species; however, identification of signaling networks is complex.⁸⁰ For example, proteomic studies, including Western array analysis, screened human carotid artery specimens for key proteins and identified numerous genes which are differentially expressed under atherosclerotic conditions, eg, apoptosis linked gene 2 (*ALG2*) or Annexin 1.^{89,90} Furthermore, metabolic and proteomic investigations of SMCs from *Apoe*^{-/-} mice under normoxic versus hypoxic conditions showed a differential regulation of key enzymes in glucose metabolism, resulting in faster glucose consumption under hypoxia and a compensatory reduction in baseline interleukin (IL)-6 secretion, which was associated with a marked upregulation of insulin-like growth factor binding protein 3.⁹¹ However, direct conclusions identifying signaling pathways remain elusive in the above-mentioned studies. Nevertheless, other studies, addressing more specific questions, did investigate signaling pathways by proteomic approaches: 2-DE identified the correlation of the strongly anti-apoptotic heat shock protein (HSP)-27 phosphorylation level with cardiovascular diseases, by identifying LDL as an important regulator of HSP27 phosphorylation involving p38–mitogen-activated protein kinase signaling in VSMCs.⁹² Moreover, 2-DE and MS revealed that paracrine secretion of platelet-derived growth factor–BB by ECs is implicated in the pathophysiological vascular remodeling induced by low shear stress, involving the phosphorylation of extracellular signal-regulated kinases (ERK)1 and 2, which belong to the mitogen-activated protein kinase family.⁹³ In addition, the importance of ERK1 and ERK2 phosphorylation was shown in vitro in bovine aortic ECs after stimulation with oxidized phospholipids using liquid chromatography–mass spectrometry analysis.⁹⁴ Supplementally, proteomics has also been proven to be of emerging interest in atrial fibrillation-associated stroke,³ cerebral infarction,⁹⁵ and focal cerebral ischemic injury,⁹⁶ identifying potential marker proteins such as HSP2 or HSP60. Furthermore, proteomic screening of prediagnostic plasma samples from postmenopausal women receiving a hormone therapy described B2M and insulin-like growth factor binding protein 4 as risk markers for CAD and stroke, respectively.⁹⁷ Considerable effort was also made to discover key proteins in PAD, which lead to the recognition of B2M and cysteine C as being associated with PAD, independently of the traditional risk factors of age, diabetes mellitus, hyperlipidemia, hypertension, and tobacco use.^{98,99}

In summary, proteomic techniques are helpful to identify marker proteins of vascular inflammation and to unravel inflammation-associated signaling cascades, especially protein phosphorylation signaling networks, which can severely affect cellular processes.¹⁰⁰

Metabolomics describes the (quantitative or qualitative) measurement of the endogenous metabolome, defined as the

entire set of metabolites (small molecules, representing intermediates of the metabolism) within 1 organism.^{81,101} Furthermore, metabolomics involves the investigation of the complex interactions of metabolites with each other (metabolism) or with other molecules (eg, genes or proteins). Metabolites, as the smallest entity of metabolomics, reflect dynamic and unique aspects of cellular homeostasis, which may provide insight into intricate molecular processes. Analytical methods to measure metabolites are MS and nuclear magnetic resonance spectroscopy.¹⁰² However, to date, there are only a limited number of studies using these methods to unravel complex disease mechanisms and subsequent therapeutic options in cardiovascular disease.^{103,104} It is noteworthy that Shah et al presented the first evaluation of heritable metabolite profiles in humans, investigating 117 individuals and 66 metabolites by quantitative MS-based metabolomics. Surprisingly, the heritabilities for many metabolites were very high, even higher than for conventional risk factors, implying a strong genetic impact on clustering of metabolic signatures in families burdened with CAD.¹⁰⁵ Another metabolomic study, combining nuclear magnetic resonance spectroscopy and gas chromatography–MS, investigated the metabolism in liver and other organs to examine the consequences of peroxisome proliferator-activated receptor (PPAR)- α loss with the help of Ppar- α -deficient mice. Ppar- α partially controls hunger and the feeling of satiety, and its lack resulted in hepatic steatosis and changes in lipid and glucose metabolism also affecting the cardiovascular system.¹⁰⁶ In addition, recent liquid chromatography–mass spectrometry metabolomics identified the plasma molecules choline, betaine, and trimethylamine *N*-oxide, all metabolites of the dietary lipid phosphatidylcholine, as risk factors for cardiovascular disease, which triggered the identification of a link between dietary lipid intake, intestinal microflora, and atherosclerosis.¹⁰⁷ Other recent metabolomic approaches expanded this finding, showing that gut microbiota affects host energy, systemic lipid metabolism, and hepatic metabolic profiles, altogether highlighting the role of gut microflora and its role in the development of metabolic diseases.^{108–110} Furthermore, metabolomics were also used to study and introduce metabolic biomarkers of stroke and cerebrovascular diseases. Jung et al were able to demonstrate, that plasma of stroke patients was characterized by the increased excretion of lactate, pyruvate, glycolate, and formate, whereas the excretion of glutamine and methanol was decreased.¹¹¹ Other recent approaches using nuclear magnetic resonance–based metabolomic analysis of cerebrospinal fluid and serum showed reduced levels of serum betaine in patients with cerebrovascular disease, perhaps indicating a population at high risk for stroke, because betaine, a methyl donor, reduces levels of homocysteine, a known risk factor for cerebrovascular disorders. Interestingly, cerebrospinal fluid metabolite profiles did more accurately predict the diagnosis of multiple sclerosis than anticipated cerebrovascular disease.¹¹²

Hence, metabolomics will provide further insight into the mechanisms of cardiovascular physiology and may lead to improved therapeutic approaches.

A main risk factor for atherosclerosis is hyperlipidemia, caused by an imbalanced lipid metabolism of multifactorial

origin. The lipidome of an organism comprises all lipid molecules, which are additionally divided into lipid classes, and their associated interacting factors. Therefore, lipidomics is of outstanding interest for atherosclerotic research, also with regard to lipid distribution within cells and biochemical mechanisms mediated by lipids. The most important methods to enable high-throughput and high-quality lipid analysis are MS and lipid biochemistry, which make simultaneous identification and quantification of hundreds of molecular lipids within 1 species possible.^{113,114} For example, comparing fractionized serum samples of diabetic patients versus healthy controls by liquid chromatography-mass spectrometry indicated that the serum concentrations of specific triacylglycerol acids are more accurate markers for insulin resistance and abdominal obesity than total serum triacylglycerol concentrations. Thus, fatty acid characteristics may become important markers identifying individual risk profiles for various diseases.¹¹⁵ Furthermore, 1 example of how lipids may affect pathway signaling has been nicely discussed by Wheelock et al, who revealed 77 biochemical pathways to be differentially affected between low and high fat cholesterol diet in mice, by combining liver transcriptomics and lipidomics data and mapping them onto a metabolic pathway database.¹¹⁶ System biology approaches like those introduced by Wheelock et al¹¹⁶ are very helpful to process high-throughput data, which is further discussed below. In addition, changes in lipid profiles, including phospholipids, ceramides, sphingomyelin, cerebroside, cholesterol, and their oxidized derivatives, may also affect or be indicative of ischemic stroke, as indicated by Fonteh and Fisher¹¹⁷ and by Fonteh et al.¹¹⁸

Protein microarrays are an emerging tool, competing with traditional gel-based methods (eg, 2-DE), offering a higher reproducibility and the possibility of high-throughput approaches. These microarrays mostly consist of thousands of immobilized proteins spotted to a glass slide and enable simultaneous analysis of various protein-protein interactions at once.^{119,120} Another example are cytokine antibody arrays, which use membrane-spotted capture antibodies to investigate the cytokine profile of biological fluids, a technique that became famous in cancer research to detect tumor markers.¹²¹ As an example of its utility in vascular inflammation, the use of a cytokine array detecting 36 proteins released from vascular endothelial growth factor (VEGF)-stimulated ECs revealed a VEGF receptor 2-PKD1 axis-dependent production of IL-6, IL-8, and growth regulated oncogene- α in ECs but not in leukocytes, pointing at differential pathways induced by VEGF-dependent signaling in different cell types.¹²² Furthermore, human cytomegalovirus, known to be proatherogenic by, eg, stimulation of angiogenesis, induced IL-6, IL-8, and granulocyte-colony stimulating factor secretion by infected ECs, as evidenced by human cytokine array screening for 174 different proteins in EC supernatants.¹²³ Again, modeling protein networks or pathways from here is still challenging and a mathematical exercise. However, there are already studies that apply quantitative mathematical models to dynamic immune interactions, although not explicitly for vascular biology.^{124,125} Overall, proteomic techniques are promising tools to unravel complex network formation.

RNA Interference

The term RNA interference (RNAi) describes an RNA-dependent gene silencing process, which is initiated by short double-stranded RNA, resulting in a reduction of targeted mRNA levels. RNAi molecules comprise sets of double-stranded RNA, short hairpin (sh)RNA, silencing RNAs (siRNAs) or endoribonuclease-prepared siRNAs. These small molecules are able to induce a reduction-of-gene-function, which may lead to a phenotypically detectable variation. In turn, this variation may be monitored by specific assays. RNAi offers the possibility of performing both small-scale studies targeting 1 gene or high-throughput approaches investigating numerous genes and their function at once, though of course careful data interpretation is needed.¹²⁶ Although there are recent reviews^{126–129} and original studies^{130,131} summarizing and investigating high-throughput RNAi screening to unravel cellular signaling in general, studies addressing signaling cascades in vascular inflammation rather concentrated on knockdown of specific gene functions instead of investigating on large-scale basis. For example, silencing of bone morphogenetic proteins/Sma and Mad related proteins signaling in human aortic ECs,¹³² downregulation of tumor necrosis factor–dependent nuclear factor- κ B activation in ECs,¹³³ or silencing of PI3-AKT signaling in human umbilical vein ECs¹³⁴ was shown to have atheroprotective effects on the vascular endothelium. Furthermore, it was shown that simultaneous downregulation of the VEGF receptor 2/3-, CXCR4-, and CCR7-dependent signaling axes via AKT, ERK1/2, and p38 signaling pathways had a greater inhibitory effect on angiogenesis and cell growth than the blockade of each individual axis.¹³⁵ These results may be of special interest regarding atherosclerosis because the CXCR4/CXCL12 axis in ECs seems to play a protective role in atherosclerosis.^{136,137} One other recent study of outstanding interest identified candidate genes involved in cellular cholesterol metabolism by transcriptional profiling of sterol-depleted HeLa cells, literature mining and a “multiple-gene” RNAi screen, which combined reverse siRNA transfection on siRNA microarrays with high-content screening microscopy and quantitative image analysis software to analyze effects on total cholesterol levels and LDL uptake efficiency.¹³⁸ Thus, these findings may offer subsequent therapeutic approaches in terms of atherosclerosis or even Niemann-Pick disease type C, which is an inherited lipid storage disorder, characterized by a defect in intracellular trafficking of exogenous cholesterol and glycosphingolipids, and in which regulators of cellular cholesterol accumulation have also been studied through an RNAi screen.¹³⁹ In addition, RNAi was helpful to unravel mechanisms important in cerebral ischemia-induced vascular and brain injury. Here, Yin et al. were able to show that Ppar δ expression in mouse aortic VSMCs can prevent ischemic brain injury by inhibition of matrix metalloproteinase-9 activation and attenuation of postischemic inflammation in mice. RNAi-mediated knockdown of matrix metalloproteinase-9 in Ppar δ knockout mice phenocopied these effects, rendering pharmacological activation of Ppar δ a promising therapeutic tool for stroke-induced vascular and neuronal damage.¹⁴⁰ Similarly to matrix metalloproteinase-9, silencing of caspase-3 in mice by siRNA

treatment also exhibited beneficial effects in the cure of stroke.¹⁴¹ Another approach, investigating the plasma concentrations of circulating angiogenesis-related factors like VEGF, placenta growth factor, and thrombospondin-1 in 184 PAD patients and in 330 paired healthy controls demonstrated an increase of TSP-1 plasma levels in the disease group. Additional *in vitro* studies, knocking down TSP-1 with siRNA in human endothelial colony-forming cells, unraveled a potential mechanism by which increased TSP-1 levels might be responsible for inadequate neovascularization. Hence, targeting TSP-1 *ex vivo* or *in vivo* might have the potential to modulate angiogenesis in PAD patients.¹⁴² Overall, RNAi is a powerful tool to investigate inflammatory networks and cellular signaling, although it is still mostly used on a small scale in the context of vascular inflammation and cardiovascular disease.

Epigenomics

Epigenomics involves the study of phenotypic or gene expression changes caused by inheritable mechanisms independent of DNA sequence, eg, DNA methylation and histone posttranslational modifications. Also, noncoding RNA alterations can be classified as epigenetic mechanisms, as they have been shown to mediate epigenetic DNA and histone modifications.¹⁴³ Epigenetic marks are increasingly being recognized as important elements underlying phenotypic variation, biological processes, inflammation, and diseases such as cancer, and large-scale epigenome projects have been set up in an attempt to create reference human epigenome maps.¹⁴⁴ High-throughput techniques enabling epigenetic analysis on a genome-wide scale include, eg, shotgun bisulfite sequencing and pyrosequencing to analyze DNA methylation,¹⁴⁵ and genome-scale chromatin immunoprecipitation with antibodies recognizing specific histone modifications or DNA methylation, followed by microarray analysis or high-throughput sequencing.^{146,147} Alternative methods to examine DNA methylation are differential methylation hybridization, which encompasses methylation-sensitive DNA restriction followed by microarray analysis of the restriction-protected, hypermethylated DNA,¹⁴⁸ bead array methylation analysis of bisulfite-treated DNA,¹⁴⁹ and base-specific cleavage combined with matrix-assisted laser desorption/ionization/time of flight.¹⁵⁰ However, epigenetics is cell dependent and subjected to environmental factors, urging disease-specific studies to uncover epigenetic changes associated with disease. Compared with, for example, cancer research, the cardiovascular field is still in its infancy of epigenetic research. Initial studies have addressed vascular inflammation-related epigenetic changes on a global level (examining global changes in epigenetics without linkage to specific gene promoters) or have focused on specific genes. For example, genomic DNA in human atherosclerotic lesions has been shown to be hypomethylated, whereas inconsistent results have been obtained in peripheral blood lymphocytes from patients with cardiovascular disease.^{151–153} Hypermethylated DNA has been detected in ischemic brain tissue after middle cerebral artery occlusion in mice and may promote cell death.^{154,155} Immunohistochemistry for specific histone methylation modifications revealed prenatal exposure to apolipoprotein E

deficiency and postnatal hypercholesterolemia to be associated with cell-specific histone methylation changes in carotid artery of mice.¹⁵⁶ Furthermore, oxidized LDL treatment of cultured human ECs induced histone phosphorylation and acetylation, both globally (as detected by Western blot analysis) and on the promoters of *MCP-1* and *IL-8* (as shown by chromatin immunoprecipitation).¹⁵⁷ Interestingly, histone modifications could be reversed by statin pretreatment.¹⁵⁷ Also methylation changes have been detected in the promoters of genes involved in atherogenesis, such as estrogen receptor α , endothelial nitric oxide synthase, and 15 lipoxygenase, as comprehensively reviewed in recent reports.^{158,159} In contrast, only few studies are available examining the relationship between epigenetics and vascular inflammation on a high-throughput, genome-wide level. For example, Breton et al investigated the effect of prenatal exposure to tobacco smoke, a risk factor for cardiovascular disease, on global and genome-wide gene-specific DNA methylation in children, using bisulfite sequencing of DNA repetitive elements and gene methylation bead array analysis of child buccal cell DNA.¹⁶⁰ Eight genes, including *AXL* and *PTPRO*, were shown to be differentially methylated on maternal smoking.¹⁶⁰ In a comparable approach, array-based genome-wide methylation profiling of peripheral blood DNA revealed that heavy smokers displayed a significantly reduced methylation of *F2RL3*, a gene with known functions in cardiovascular disease.¹⁶¹ Furthermore, differential methylation hybridization discovered 204 gene promoter regions to be differentially methylated in the fetal liver genome of mouse embryos with prenatal low-protein diet. Among these was the promoter of liver X receptor (*Lxr*) α , a nuclear receptor involved in cholesterol metabolism. *Lxr* α hypermethylation was linked to reduced expression of *Lxr* α and its target genes, speculating long-term effects on lipid metabolism and potentially cardiovascular disease.¹⁴⁸ Movassagh et al analyzed DNA methylation in human end-stage cardiomyopathy samples using methylated DNA immunoprecipitation and microarray analysis, and identified 3 angiogenesis-related genetic loci that were differentially methylated.¹⁶² Expression of the genes was furthermore shown to be significantly altered between diseased and control hearts.¹⁶²

Much more research is required in the field of cardiovascular epigenetics to increase our insights into disease-associated epigenetic patterns, and to clarify whether epigenetic changes truly contribute to pathogenesis or whether they are merely a result of pathological processes. Global hepatic DNA methylation in postmortem samples of young adults, measured by bisulfite sequencing, did not indicate an association of global DNA methylation with subclinical atherosclerosis.¹⁶³ However, this does not exclude the possibility that specific epigenetic marks are causally associated with pathogenesis, which could offer therapeutic options given the reversible nature of epigenetic modifications.

Analysis and Integration of High-Throughput Data: Network Modeling and Systems-Based Biology

All these “-omics” techniques generate an enormous wealth of data, urging computational methods to extract all con-




Figure. A systems biology approach to atherosclerosis. To uncover mechanisms underlying multifactorial diseases, such as atherosclerosis, high-throughput “omics” techniques are applied in clinical studies and experimental models, including animal studies and in vitro experiments. Integration of the resulting large-scale data sets in combination with intensive literature and database mining allows the modeling of complex biological networks representing biological processes, which on perturbation can shift from a healthy to a diseased state. Such a systems biology approach has an unprecedented power to uncover disease-associated mechanisms, which in turn provide a strong base for therapeutic drug design. It can also trigger the discovery of new disease biomarkers in the hope of enabling improved disease classification and prediction, bringing personalized medicine a step closer. RNAi indicates RNA interference.

cealed information. Systems biology aims to model biological processes as networks, generating graphical maps consisting of nodes and edges representing the individual system components and their relations, respectively. For a protein network, for example, edges can represent physical protein interactions, functional similarities, or the regulation of 1 protein by another. A high internal connection between a subset of nodes results in their clustering into modules, which represent key control points within the network. By combining multiple high-throughput data sets generated by in vitro and in vivo studies, with intensive literature mining and biomolecular databases of, eg, gene classification, protein interactions and pathways, network analysis has the strength to reveal disease-associated components and connections that would not have been discovered with classical approaches.^{164,165} Furthermore, mathematical models can be developed to simulate network behavior on perturbations. Iterative optimization of the model by additional, hypothesis-driven system perturbations and data integration is essential to increase its precision and its ability to accurately predict the dynamics of the system studied (for example, a patient’s response to drugs, or disease progression) (Figure).^{164,165} Although the

development of such mathematical, disease-predicting models is still in its infancy, network analysis of high throughput data sets has already proven a powerful tool to increase our insights into complex diseases.

In the context of vascular inflammation and atherosclerosis, network analysis combining transcriptomics and literature mining revealed candidate gene sets involved in human in-stent restenosis⁴¹ and coronary and carotid atherosclerosis.^{43,166} Transcriptional profiling of lesions in atherosclerosis-prone mice with a human-like hypercholesterolemia and a genetic switch to lower plasma LDL cholesterol revealed a set of cholesterol-responsive atherosclerosis genes, of which a subset could be modeled into a gene regulatory network of foam cell formation based on additional expression profiling of acetylated LDL-exposed macrophages targeted with specific siRNAs.⁴⁵ In the same context, network modeling and pathway analysis of transcriptomics data from oxidized LDL-treated macrophages identified biological processes relevant to foam cell formation, such as regulation of macrophage differentiation and lipoprotein catabolic processes.¹⁶⁴ A pathway analysis approach has also been successfully applied on CAD-associated GWAS data, identifying perturbations in

VSMC contraction, among others, as a key process in atherosclerosis.¹⁶⁷ Furthermore, gene expression profiling, promoter sequence analysis, and temporal expression comparison between transcription factors and gene targets were integrated to model the dynamic transcriptional response of Toll-like receptor signaling in macrophages.^{168,169} In atherosclerosis-prone mice, network modeling based on liver transcriptome and lipid metabolome data sets revealed a close link between liver inflammation and lipid metabolism on dietary cholesterol intake, and identified transcriptional regulators coregulating both processes.⁶⁰ In addition, a systems biology approach combining transcriptional profiling, proteomics, cytokine arrays, and pathway analysis revealed genes, proteins, and biological processes associated with late-phase responses of lipopolysaccharide-stimulated rat ECs and showed lipopolysaccharide to induce, for instance, nuclear factor- κ B-mediated inflammatory signaling, in addition to self-protective responses by upregulating mediators of anti-inflammation, antiapoptosis, and antioxidation.¹⁷⁰

Using transcriptional profiling of swine EC samples isolated from arterial regions with variable atherosclerosis susceptibility, gene coexpression networks were modeled on the basis of coregulated expression and suggested the presence of endoplasmic reticulum and oxidative stress in susceptible sites.⁴⁹ Also interindividual genetic variability can be exploited to subdivide genes into coregulated modules. For example, intercrosses of inbred mouse strains with dramatic differences in high-density lipoprotein metabolism were used to model gene coexpression networks and identify modules that were significantly associated with high-density lipoprotein cholesterol levels.¹⁷¹ Interestingly, some of the genes within these modules had previously been identified as candidate genes associated with plasma lipids in human GWASs.¹⁷ Comparably, coexpression networks based on expression profiles of EC cultures from multiple heart transplant donors resulted in the identification of pathways, novel gene functions and regulatory relationships in the human EC response to the oxidized phospholipid oxidized palmitoyl arachidonyl phosphatidylcholine.^{28,172} For instance, the unfolded protein response and the transcription factor ATF4 were revealed as important mediators of inflammatory IL-8 production in oxidized palmitoyl arachidonyl phosphatidylcholine-stimulated ECs,¹⁷² and GPR39 was found to control the expression of heme oxygenase 1, a known regulator of inflammation, by combination of the modeled network with CAD-associated GWAS data sets.²⁸ The latter furthermore exemplifies that the integration of expression profiling or eQTL mapping with GWAS data increases the power to detect disease-associated genes, as also discussed above, and the simultaneous analysis of genotype, transcriptome, and clinical trait can even enable the construction of networks that can predict causal relationships between genes and disease.³⁶

A systems biology approach has also been used to meet the complexity of the proangiogenic function of the VEGF family, not only in terms of CAD, but also for stroke and PAD.¹⁷³ In addition, a predictive network model, evaluating the transcriptome of whole blood from a mouse model of neuroprotection in ischemic stroke, was described, and it proved to be able to precisely predict mammalian system behavior under novel conditions.¹⁷⁴

Far from being complete, these examples demonstrate how network modeling has contributed to the analysis of high-throughput data sets and the identification of new cardiovascular disease-associated genes and pathways that would not have been discovered with the traditional, single-analysis approaches. In this way, networks could trigger the development of new diagnostic markers (eg, of atherosclerosis) by revealing targets that accurately predict lesion vulnerability.⁴⁴ Accordingly, systems biology and predictive network modeling may be used to develop concrete clinical applications helping to improve, for example, patient selection or monitoring of stroke preventive intervention.¹⁷⁴ In addition, the subdivision of networks of multifactorial diseases in subnetworks or modules indicates that multiple genes and pathways probably need to be tackled together to treat the disease as efficient as possible, and could offer help in the design of a combination therapy. For more detailed information on network modeling, and an overview of currently available tools and databases, we refer to previous in-depth reviews.^{116,164,165,175}

Evaluation and Conclusions

High-throughput technologies comprising all omics techniques, as well as RNAi, offer great advantages to profile the complex pathophysiology of human cardiovascular disease. The combination of clinical trait QTLs and eQTLs enables the matching of a specific chromosomal locus to a phenotypic trait through gene expression. In addition, proteomic techniques such as 2-DE or LC/MS offer the possibility of identifying altered or differentially expressed proteins, which influence cellular signaling cascades or protein phosphorylation. In the same context, protein arrays explore protein contents of biological fluids. Moreover, metabolomics permits insight into dynamic and unique aspects of cellular homeostasis and general metabolism, similar to lipidomics, which helps to understand imbalances in lipid metabolism, the latter being of outstanding interest in atherosclerosis. In addition, approaches using RNAi arrays enable the specific knockdown of numerous target genes, leading to the detection of signaling pathways and subsequent phenotypic changes. Finally, epigenomics is rapidly gaining interest. It is not only expected to fill the gaps in our knowledge of cardiovascular disease risk but also represents an interesting area for drug discovery, given the reversible nature of epigenetic patterns.

It is expected that the refinement, expansion, and cost reduction of high-throughput methods in all these fields will increase data generation even more. However, the main challenge will be to extract all hidden information to enhance our insights in the pathophysiological processes of cardiovascular disease, and to trigger clinical application. For example, genomic information is not yet widely applied in clinical cardiology, in contrast to clinical practice in oncology. One reason could be the missing heritability of GWAS-identified risk SNPs, which may be due to low-frequency variants and epigenetics. Another reason is the lack of functional annotations of these SNPs and their links with cardiovascular disease. To fulfill the requirements of a clinical use, for example as a biomarker, these polymorphisms would have to meet the criteria of a preclinical marker, which is able to indicate pathogenic mechanisms for concrete diagnostic or

interventional approaches. Likewise, epigenetic changes require translation into associated alterations in gene regulation and cellular signaling. Therefore, integration of all omics techniques is of extreme importance to extract functional links between omics-generated data sets and pathological processes, and to open the way for novel drug discovery. In this context, combination of genomics with transcriptomics has indeed proven to be very successful in identifying disease-associated genes and pathways. Enhanced integration of multidimensional data sets will unequivocally require systems biology approaches. Ultimately, it is hoped that accurate network modeling of diseases in such systems biology approach can be used to predict therapeutic responses and potential side effects and to trigger personalized medicine by integrating complex genetic and environmental aspects of multifactorial diseases, such as cardiovascular disease. Given these extreme challenges, the future success of systems biology requires a continuous expansion and refinement of software for high-throughput data acquisition, storage and integrative analysis through network-based approaches. Obviously, clear ethical guidelines how to deal with results, also in terms of, for example, life insurance, will be indispensable.

Overall, high-throughput techniques are promising tools to unravel the complex biological networks underlying vascular inflammation and atherosclerosis.

Sources of Funding

This work was supported by Deutsche Forschungsgemeinschaft (FOR809), the European Research Council, the Fondation Leducq (to C.W.), by the Alexander von Humboldt Foundation (to H.N.).

Disclosures

Prof Dr med Weber is a shareholder of Carolus Therapeutics Inc.

References

- Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. *Nat Med*. 2011;17:1410–1422.
- Dichgans M. Genetics of ischaemic stroke. *Lancet Neurol*. 2007;6:149–161.
- Goudarzi M, Ross MM, Zhou W, Van Meter A, Deng J, Martin LM, Martin C, Liotta L, Petricoin E, Ad N. Development of a novel proteomic approach for mitochondrial proteomics from cardiac tissue from patients with atrial fibrillation. *J Proteome Res*. 2011;10:3484–3492.
- Potteaux S, Ait-Oufella H, Mallat Z. Mouse models of atherosclerosis. *Drug Discovery Today: Disease Models*. 2006;4:165–170.
- Fuster JJ, Fernandez P, Gonzalez-Navarro H, Silvestre C, Nabah YN, Andres V. Control of cell proliferation in atherosclerosis: insights from animal models and human studies. *Cardiovasc Res*. 2010;86:254–264.
- Tannock LR, King VL. Animal models of atherosclerosis: more than mice. *Atherosclerosis*. 2010;212:32–33.
- van Ditzhuijzen NS, van den Heuvel M, Sorop O, van Duin RW, Krabbendam-Peters I, van Haeren R, Ligthart JM, Witberg KT, Duncker DJ, Regar E, van Beusekom HM, van der Giessen WJ. Invasive coronary imaging in animal models of atherosclerosis. *Neth Heart J*. 2011;19:442–446.
- Vilahur G, Padro T, Badimon L. Atherosclerosis and thrombosis: insights from large animal models. *J Biomed Biotechnol*. 2011;2011:907575.
- Schadt EE. Molecular networks as sensors and drivers of common human diseases. *Nature*. 2009;461:218–223.
- Altshuler D, Daly MJ, Lander ES. Genetic mapping in human disease. *Science*. 2008;322:881–888.
- Kathiresan S, Voight BF, Purcell S, Musunuru K, Ardissino D, Mannucci PM, Anand S, Engert JC, Samani NJ, Schunkert H, Erdmann J, Reilly MP, Rader DJ, Morgan T, Spertus JA, Stoll M, Girelli D, McKeown PP, Patterson CC, Siscovick DS, O'Donnell CJ, Elosua R, Peltonen L, Salomaa V, Schwartz SM, Melander O, Altshuler D, Ardissino D, Merlini PA, Berzuini C, Bernardinelli L, Peyvandi F, Tubaro M, Celli P, Ferrario M, Fetiveau R, Marziliano N, Casari G, Galli M, Ribichini F, Rossi M, Bernardi F, Zonzin P, Piazza A, Mannucci PM, Schwartz SM, Siscovick DS, Yee J, Friedlander Y, Elosua R, Marrugat J, Lucas G, Subirana I, Sala J, Ramos R, Kathiresan S, Meigs JB, Williams G, Nathan DM, MacRae CA, O'Donnell CJ, Salomaa V, Havulinna AS, Peltonen L, Melander O, Berglund G, Voight BF, Kathiresan S, Hirschhorn JN, Asselta R, Duga S, Spreafico M, Musunuru K, Daly MJ, Purcell S, Voight BF, Purcell S, Nemes J, Korn JM, McCarroll SA, Schwartz SM, Yee J, Kathiresan S, Lucas G, Subirana I, Elosua R, Surti A, Guiducci C, Gianniny L, Mirel D, Parkin M, Burt N, Gabriel SB, Samani NJ, Thompson JR, Braund PS, Wright BJ, Balmforth AJ, Ball SG, Hall AS, Schunkert H, Erdmann J, Linsel-Nitschke P, Lieb W, Ziegler A, König I, Hengstenberg C, Fischer M, Stark K, Grosshennig A, Preuss M, Wichmann HE, Schreiber S, Schunkert H, Samani NJ, Erdmann J, Ouwendahl W, Hengstenberg C, Deloukas P, Scholz M, Cambien F, Reilly MP, Li M, Chen Z, Wilensky R, Matthai W, Qasim A, Hakonarson HH, Devaney J, Burnett MS, Pichard AD, Kent KM, Satler L, Lindsay JM, Waksman R, Knouff CW, Waterworth DM, Walker MC, Mooser V, Epstein SE, Rader DJ, Scheffold T, Berger K, Stoll M, Hüge A, Girelli D, Martinelli N, Olivieri O, Corrocher R, Morgan T, Spertus JA, McKeown P, Patterson CC, Schunkert H, Erdmann E, Linsel-Nitschke P, Lieb W, Ziegler A, König IR, Hengstenberg C, Fischer M, Stark K, Grosshennig A, Preuss M, Wichmann HE, Schreiber S, Holm H, Thorleifsson G, Thorsteinsdottir U, Stefansson K, Engert JC, Do R, Xie C, Anand S, Kathiresan S, Ardissino D, Mannucci PM, Siscovick D, O'Donnell CJ, Samani NJ, Melander O, Elosua R, Peltonen L, Salomaa V, Schwartz SM, Altshuler D. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. *Nat Genet*. 2009;41:334–341.
- Schunkert H, König IR, Kathiresan S, Reilly MP, Assimes TL, Holm H, Preuss M, Stewart AF, Barbalic M, Gieger C, Absher D, Aherrahou Z, Allayee H, Altshuler D, Anand SS, Andersen K, Anderson JL, Ardissino D, Ball SG, Balmforth AJ, Barnes TA, Becker DM, Becker LC, Berger K, Bis JC, Boekholdt SM, Boerwinkle E, Braund PS, Brown MJ, Burnett MS, Buyschaert I, Carlquist JF, Chen L, Cichon S, Codd V, Davies RW, Dedoussis G, Dehghan A, Demissie S, Devaney JM, Diemert P, Do R, Doering A, Eifert S, Mokhtari NE, Ellis SG, Elosua R, Engert JC, Epstein SE, de Faire U, Fischer M, Folsom AR, Freyer J, Gigante B, Girelli D, Gretarsdottir S, Gudnason V, Gulcher JR, Halperin E, Hammond N, Hazen SL, Hofman A, Horne BD, Illig T, Iribarren C, Jones GT, Jukema JW, Kaiser MA, Kaplan LM, Kastelein JJ, Khaw KT, Knowles JW, Kolovou G, Kong A, Laaksonen R, Lambrechts D, Leander K, Lettre G, Li M, Lieb W, Loley C, Lotery AJ, Mannucci PM, Maouche S, Martinelli N, McKeown PP, Meisinger C, Meitinger T, Melander O, Merlini PA, Sandhu MS, Morgan T, Muhleisen T, Muhlestein JB, Munzel T, Musunuru K, Nahrstaedt J, Nelson CP, Nothen MM, Olivieri O, Patel RS, Patterson CC, Peters A, Peyvandi F, Qu L, Quyyumi AA, Rader DJ, Rallidis LS, Rice C, Rosendaal FR, Rubin D, Salomaa V, Sampietro ML, Sandhu MS, Schadt E, Schafer A, Schillert A, Schreiber S, Schrezenmeier J, Schwartz SM, Siscovick DS, Sivananthan M, Sivapalaratnam S, Smith A, Smith TB, Snoop JD, Soranzo N, Spertus JA, Stark K, Stirrups K, Stoll M, Tang WH, Tenstedt S, Thorgerisson G, Thorleifsson G, Tomaszewski M, Uitterlinden AG, van Rij AM, Voight BF, Wareham NJ, Wells GA, Wichmann HE, Wild PS, Willenborg C, Witteman JC, Wright BJ, Ye S, Zeller T, Ziegler A, Cambien F, Goodall AH, Cupples LA, Quertermous T, Marz W, Hengstenberg C, Blankenberg S, Ouwendahl WH, Hall AS, Deloukas P, Thompson JR, Stefansson K, Roberts R, Thorsteinsdottir U, O'Donnell CJ, McPherson R, Erdmann J, Samani NJ. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. *Nat Genet*. 2011;43:333–338.
- Schunkert H, Erdmann J, Samani NJ. Genetics of myocardial infarction: a progress report. *Eur Heart J*. 2010;31:918–925.
- Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R, Heath SC, Timpson NJ, Najjar SS, Stringham HM, Strait J, Duren WL, Maschio A, Busonero F, Mulas A, Albai G, Swift AJ, Morken MA, Narisu N, Bennett D, Parish S, Shen H, Galan P, Meneton P, Hercberg S, Zelenika D, Chen WM, Li Y, Scott LJ, Scheet PA, Sundvall J, Watanabe RM, Nagaraja R, Ebrahim S, Lawlor DA, Ben-Shlomo Y, Davey-Smith G, Shuldiner AR, Collins R, Bergman RN, Uda M, Tuomilehto J, Cao A, Collins FS, Lakatta E, Lathrop GM, Boehnke M, Schlessinger D, Mohlke KL, Abecasis GR. Newly identified loci that

- influence lipid concentrations and risk of coronary artery disease. *Nat Genet.* 2008;40:161–169.
15. Kathiresan S, Willer CJ, Peloso GM, Demissie S, Musunuru K, Schadt EE, Kaplan L, Bennett D, Li Y, Tanaka T, Voight BF, Bonnycastle LL, Jackson AU, Crawford G, Surti A, Guiducci C, Burt NP, Parish S, Clarke R, Zelenika D, Kubalanza KA, Morken MA, Scott LJ, Stringham HM, Galan P, Swift AJ, Kuusisto J, Bergman RN, Sundvall J, Laakso M, Ferrucci L, Scheet P, Sanna S, Uda M, Yang Q, Lunetta KL, Dupuis J, de Bakker PI, O'Donnell CJ, Chambers JC, Kooner JS, Herberg S, Meneton P, Lakatta EG, Scuteri A, Schlessinger D, Tuomilehto J, Collins FS, Groop L, Altshuler D, Collins R, Lathrop GM, Melander O, Salomaa V, Peltonen L, Orho-Melander M, Ordovas JM, Boehnke M, Abecasis GR, Mohlke KL, Cupples LA. Common variants at 30 loci contribute to polygenic dyslipidemia. *Nat Genet.* 2009;41:56–65.
 16. Aulchenko YS, Ripatti S, Lindqvist I, Boomsma D, Heid IM, Pramstaller PP, Penninx BW, Janssens AC, Wilson JF, Spector T, Martin NG, Pedersen NL, Kyvik KO, Kaprio J, Hofman A, Freimer NB, Jarvelin MR, Gyllenstein U, Campbell H, Rudan I, Johansson A, Marroni F, Hayward C, Vitart V, Jonasson I, Pattaro C, Wright A, Hastie N, Pichler I, Hicks AA, Falchi M, Willemsen G, Hottenga JJ, de Geus EJ, Montgomery GW, Whitfield J, Magnusson P, Saharinen J, Perola M, Silander K, Isaacs A, Sijbrands EJ, Uitterlinden AG, Witteman JC, Oostra BA, Elliott P, Ruokonen A, Sabatti C, Gieger C, Meitinger T, Kronenberg F, Doring A, Wichmann HE, Smit JH, McCarthy MI, van Duijn CM, Peltonen L. Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. *Nat Genet.* 2009;41:47–55.
 17. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, Pirruccello JP, Ripatti S, Chasman DI, Willer CJ, Johansen CT, Fouchier SW, Isaacs A, Peloso GM, Barbalic M, Ricketts SL, Bis JC, Aulchenko YS, Thorleifsson G, Feitosa MF, Chambers J, Orho-Melander M, Melander O, Johnson T, Li X, Guo X, Li M, Shin Cho Y, Jin Go M, Jin Kim Y, Lee JY, Park T, Kim K, Sim X, Twee-Hee Ong R, Croteau-Chonka DC, Lange LA, Smith JD, Song K, Hua Zhao J, Yuan X, Luan J, Lamina C, Ziegler A, Zhang W, Zee RY, Wright AF, Witteman JC, Wilson JF, Willemsen G, Wichmann HE, Whitfield JB, Waterworth DM, Wareham NJ, Waeber G, Vollenweider P, Voight BF, Vitart V, Uitterlinden AG, Uda M, Tuomilehto J, Thompson JR, Tanaka T, Surakka I, Stringham HM, Spector TD, Soranzo N, Smit JH, Sinisalo J, Silander K, Sijbrands EJ, Scuteri A, Scott J, Schlessinger D, Sanna S, Salomaa V, Saharinen J, Sabatti C, Ruokonen A, Rudan I, Rose LM, Roberts R, Rieder M, Psaty BM, Pramstaller PP, Pichler I, Perola M, Penninx BW, Pedersen NL, Pattaro C, Parker AN, Pare G, Oostra BA, O'Donnell CJ, Nieminen MS, Nickerson DA, Montgomery GW, Meitinger T, McPherson R, McCarthy MI, McArdle W, Masson D, Martin NG, Marroni F, Mangino M, Magnusson PK, Lucas G, Luben R, Loos RJ, Lokki ML, Lettre G, Langenberg C, Launer LJ, Lakatta EG, Laaksonen R, Kyvik KO, Kronenberg F, König IR, Khaw KT, Kaprio J, Kaplan LM, Johansson A, Jarvelin MR, Janssens AC, Ingelsson E, Igl W, Kees Hovingh G, Hottenga JJ, Hofman A, Hicks AA, Hengstenberg C, Heid IM, Hayward C, Havulinna AS, Hastie ND, Harris TB, Haritunians T, Hall AS, Gyllenstein U, Guiducci C, Groop LC, Gonzalez E, Gieger C, Freimer NB, Ferrucci L, Erdmann J, Elliott P, Ejebe KG, Doring A, Dominiczak AF, Demissie S, Deloukas P, de Geus EJ, de Faire U, Crawford G, Collins FS, Chen YD, Caulfield MJ, Campbell H, Burt NP, Bonnycastle LL, Boomsma DI, Boekholdt SM, Bergman RN, Barroso I, Bandinelli S, Ballantyne CM, Assimes TL, Quertermous T, Altshuler D, Seielstad M, Wong TY, Tai ES, Feranil AB, Kuzawa CW, Adair LS, Taylor HA Jr, Borecki IB, Gabriel SB, Wilson JG, Holm H, Thorsteinsdottir U, Gudnason V, Krauss RM, Mohlke KL, Ordovas JM, Munroe PB, Kooner JS, Tall AR, Hegele RA, Kastelein JI, Schadt EE, Rotter JJ, Boerwinkle E, Strachan DP, Mooser V, Stefansson K, Reilly MP, Samani NJ, Schunkert H, Cupples LA, Sandhu MS, Ridker PM, Rader DJ, van Duijn CM, Peltonen L, Abecasis GR, Boehnke M, Kathiresan S. Biological, clinical and population relevance of 95 loci for blood lipids. *Nature.* 2010;466:707–713.
 18. Morgan TM, Krumholz HM, Lifton RP, Spertus JA. Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study. *JAMA.* 2007;297:1551–1561.
 19. Chico TJ, Milo M, Crossman DC. The genetics of cardiovascular disease: new insights from emerging approaches. *J Pathol.* 2010;220:186–197.
 20. Roy H, Bhardwaj S, Yla-Herttuala S. Molecular genetics of atherosclerosis. *Hum Genet.* 2009;125:467–491.
 21. Nelson PR, O'Malley KA, Feezor RJ, Moldawer LL, Seeger JM. Genomic and proteomic determinants of lower extremity revascularization failure: rationale and study design. *J Vasc Surg.* 2007;45(suppl A):A82–A91.
 22. Tromp G, Kuivaniemi H. Developments in genomics to improve understanding, diagnosis and management of aneurysms and peripheral artery disease. *Eur J Vasc Endovasc Surg.* 2009;38:676–682.
 23. Knowles JW, Assimes TL, Li J, Quertermous T, Cooke JP. Genetic susceptibility to peripheral arterial disease: a dark corner in vascular biology. *Arterioscler Thromb Vasc Biol.* 2007;27:2068–2078.
 24. Kullo IJ, Fan J, Pathak J, Savova GK, Ali Z, Chute CG. Leveraging informatics for genetic studies: use of the electronic medical record to enable a genome-wide association study of peripheral arterial disease. *J Am Med Inform Assoc.* 2010;17:568–574.
 25. McCarty CA, Chisholm RL, Chute CG, Kullo IJ, Jarvik GP, Larson EB, Li R, Masys DR, Ritchie MD, Roden DM, Struwing JP, Wolf WA. The eMERGE network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies. *BMC Med Genomics.* 2011;4:13.
 26. Berisha SZ, Smith JD. Combining genome-wide data from humans and animal models of dyslipidemia and atherosclerosis. *Curr Opin Lipidol.* 2011;22:100–105.
 27. Smith JD, Peng DQ, Dansky HM, Settle M, Baglione J, Le Goff W, Chakrabarti E, Xu Y, Peng X. Transcriptome profile of macrophages from atherosclerosis-sensitive and atherosclerosis-resistant mice. *Mamm Genome.* 2006;17:220–229.
 28. Romanoski CE, Che N, Yin F, Mai N, Poulard D, Civelek M, Pan C, Lee S, Vakili L, Yang WP, Kayne P, Mungro IN, Araujo JA, Berliner JA, Lusis AJ. Network for activation of human endothelial cells by oxidized phospholipids: a critical role of heme oxygenase 1. *Circ Res.* 2011;109:e27–41.
 29. Wang SS, Schadt EE, Wang H, Wang X, Ingram-Drake L, Shi W, Drake TA, Lusis AJ. Identification of pathways for atherosclerosis in mice: integration of quantitative trait locus analysis and global gene expression data. *Circ Res.* 2007;101:e11–e30.
 30. Emilsson V, Thorleifsson G, Zhang B, Leonardson AS, Zink F, Zhu J, Carlson S, Helgason A, Walters GB, Gunnarsdottir S, Mouty M, Steinthorsdottir V, Eiriksdottir GH, Bjornsdottir G, Reynisdottir I, Gudbjartsson D, Helgadóttir A, Jonasdóttir A, Jonasdóttir A, Styrkarsdóttir U, Gretarsdóttir S, Magnusson KP, Stefansson H, Fossdal R, Kristjansson K, Gislason HG, Stefansson T, Leifsson BG, Thorsteinsdottir U, Lamb JR, Gulcher JR, Reitman ML, Kong A, Schadt EE, Stefansson K. Genetics of gene expression and its effect on disease. *Nature.* 2008;452:423–428.
 31. Schadt EE, Molony C, Chudin E, Hao K, Yang X, Lum PY, Kasarskis A, Zhang B, Wang S, Suver C, Zhu J, Millstein J, Sieberts S, Lamb J, GuhaThakurta D, Derry J, Storey JD, Avila-Campillo I, Kruger MJ, Johnson JM, Rohl CA, van Nas A, Mehrabian M, Drake TA, Lusis AJ, Smith RC, Guengerich FP, Strom SC, Schuetz E, Rushmore TH, Ulrich R. Mapping the genetic architecture of gene expression in human liver. *PLoS Biol.* 2008;6:e107.
 32. Yang X, Peterson L, Thieringer R, Deignan JL, Wang X, Zhu J, Wang S, Zhong H, Stepanians S, Beaulaurier J, Wang IM, Rosa R, Cumiskey AM, Luo JM, Luo Q, Shah K, Xiao J, Nickle D, Plump A, Schadt EE, Lusis AJ, Lum PY. Identification and validation of genes affecting aortic lesions in mice. *J Clin Invest.* 2010;120:2414–2422.
 33. Chung CM, Lin TH, Chen JW, Leu HB, Yang HC, Ho HY, Ting CT, Sheu SH, Tsai WC, Chen JH, Lin SJ, Chen YT, Pan WH. A genome-wide association study reveals a quantitative trait locus of adiponectin on CDH13 that predicts cardiometabolic outcomes. *Diabetes.* 2011;60:2417–2423.
 34. Keum S, Marchuk DA. A locus mapping to mouse chromosome 7 determines infarct volume in a mouse model of ischemic stroke. *Circulation Cardiovascular genetics.* 2009;2:591–598.
 35. Smith JD, Bhasin JM, Baglione J, Settle M, Xu Y, Barnard J. Atherosclerosis susceptibility loci identified from a strain intercross of apolipoprotein E-deficient mice via a high-density genome scan. *Arterioscler Thromb Vasc Biol.* 2006;26:597–603.
 36. Schadt EE, Lamb J, Yang X, Zhu J, Edwards S, Guhathakurta D, Sieberts SK, Monks S, Reitman M, Zhang C, Lum PY, Leonardson A, Thieringer R, Metzger JM, Yang L, Castle J, Zhu H, Kash SF, Drake TA, Sachs A, Lusis AJ. An integrative genomics approach to infer causal associations between gene expression and disease. *Nat Genet.* 2005;37:710–717.
 37. Chen Y, Zhu J, Lum PY, Yang X, Pinto S, MacNeil DJ, Zhang C, Lamb J, Edwards S, Sieberts SK, Leonardson A, Castellini LW, Wang S, Champy MF, Zhang B, Emilsson V, Doss S, Ghazalpour A, Horvath S,

- Drake TA, Lusis AJ, Schadt EE. Variations in DNA elucidate molecular networks that cause disease. *Nature*. 2008;452:429–435.
38. Yang Q, Khoury MJ, Botto L, Friedman JM, Flanders WD. Improving the prediction of complex diseases by testing for multiple disease-susceptibility genes. *Am J Hum Genet*. 2003;72:636–649.
 39. Humphries SE, Ridker PM, Talmud PJ. Genetic testing for cardiovascular disease susceptibility: a useful clinical management tool or possible misinformation? *Arterioscler Thromb Vasc Biol*. 2004;24:628–636.
 40. Bijns AP, Lutgens E, Ayoubi T, Kuiper J, Horrevoets AJ, Daemen MJ. Genome-wide expression studies of atherosclerosis: critical issues in methodology, analysis, interpretation of transcriptomics data. *Arterioscler Thromb Vasc Biol*. 2006;26:1226–1235.
 41. Ashley EA, Ferrara R, King JY, Vailaya A, Kuchinsky A, He X, Byers B, Gerckens U, Oblin S, Tsalenko A, Soito A, Spin JM, Tabibiazar R, Connolly AJ, Simpson JB, Grube E, Quertermous T. Network analysis of human in-stent restenosis. *Circulation*. 2006;114:2644–2654.
 42. Sluimer JC, Kisters N, Cleutjens KB, Volger OL, Horrevoets AJ, van den Akker LH, Bijns AP, Daemen MJ. Dead or alive: gene expression profiles of advanced atherosclerotic plaques from autopsy and surgery. *Physiol Genomics*. 2007;30:335–341.
 43. Cagnin S, Biscuola M, Patuzzo C, Trabetti E, Pasquali A, Laveder P, Faggian G, Iafrancesco M, Mazzucco A, Pignatti PF, Lanfranchi G. Reconstruction and functional analysis of altered molecular pathways in human atherosclerotic arteries. *BMC Genomics*. 2009;10:13.
 44. Tabibiazar R, Wagner RA, Ashley EA, King JY, Ferrara R, Spin JM, Sanan DA, Narasimhan B, Tibshirani R, Tsao PS, Efron B, Quertermous T. Signature patterns of gene expression in mouse atherosclerosis and their correlation to human coronary disease. *Physiol Genomics*. 2005;22:213–226.
 45. Skogsberg J, Lundstrom J, Kovacs A, Nilsson R, Noori P, Maleki S, Kohler M, Hamsten A, Tegner J, Bjorkegren J. Transcriptional profiling uncovers a network of cholesterol-responsive atherosclerosis target genes. *PLoS Genet*. 2008;4:e1000036.
 46. Mak S, Sun H, Acevedo F, Shimmin LC, Zhao L, Teng BB, Hixson JE. Differential expression of genes in the calcium-signaling pathway underlies lesion development in the LDb mouse model of atherosclerosis. *Atherosclerosis*. 2010;213:40–51.
 47. Herrera VM, Didishvili T, Lopez LV, Ruiz-Opazo N. Differential regulation of functional gene clusters in overt coronary artery disease in a transgenic atherosclerosis-hypertensive rat model. *Mol Med*. 2002;8:367–375.
 48. Geary RL, Wong JM, Rossini A, Schwartz SM, Adams LD. Expression profiling identifies 147 genes contributing to a unique primate neointimal smooth muscle cell phenotype. *Arterioscler Thromb Vasc Biol*. 2002;22:2010–2016.
 49. Civelek M, Manduchi E, Riley RJ, Stoeckert CJ Jr, Davies PF. Coronary artery endothelial transcriptome in vivo: identification of endoplasmic reticulum stress and enhanced reactive oxygen species by gene connectivity network analysis. *Circ Cardiovasc Genet*. 2011;4:243–252.
 50. McCaffrey TA, Fu C, Du B, Eksinar S, Kent KC, Bush H Jr, Kreiger K, Rosengart T, Cybulsky MI, Silverman ES, Collins T. High-level expression of Egr-1 and Egr-1-inducible genes in mouse and human atherosclerosis. *J Clin Invest*. 2000;105:653–662.
 51. Adams LD, Geary RL, Li J, Rossini A, Schwartz SM. Expression profiling identifies smooth muscle cell diversity within human intima and plaque fibrous cap: loss of RGS5 distinguishes the cap. *Arterioscler Thromb Vasc Biol*. 2006;26:319–325.
 52. Civelek M, Manduchi E, Riley RJ, Stoeckert CJ Jr, Davies PF. Chronic endoplasmic reticulum stress activates unfolded protein response in arterial endothelium in regions of susceptibility to atherosclerosis. *Circ Res*. 2009;105:453–461.
 53. Fang Y, Shi C, Manduchi E, Civelek M, Davies PF. MicroRNA-10a regulation of proinflammatory phenotype in athero-susceptible endothelium in vivo and in vitro. *Proc Natl Acad Sci U S A*. 2010;107:13450–13455.
 54. Paul A, Yechoor V, Raja R, Li L, Chan L. Microarray gene profiling of laser-captured cells: a new tool to study atherosclerosis in mice. *Atherosclerosis*. 2008;200:257–263.
 55. Beer M, Doepping S, Hildner M, Weber G, Grabner R, Hu D, Mohanta SK, Srikakulapu P, Weih F, Habenicht AJ. Laser-capture microdissection of hyperlipidemic/ApoE^{-/-} mouse aorta atherosclerosis. *Methods Mol Biol*. 2011;755:417–428.
 56. Tuomisto TT, Korkeala A, Rutanen J, Viita H, Brasen JH, Riekkinen MS, Rissanen TT, Karkola K, Kiraly Z, Kolble K, Yla-Herttuala S. Gene expression in macrophage-rich inflammatory cell infiltrates in human atherosclerotic lesions as studied by laser microdissection and DNA array: overexpression of HMG-CoA reductase, colony stimulating factor receptors, CD11A/CD18 integrins, and interleukin receptors. *Arterioscler Thromb Vasc Biol*. 2003;23:2235–2240.
 57. Grabner R, Lotzer K, Dopping S, Hildner M, Radke D, Beer M, Spanbroek R, Lippert B, Reardon CA, Getz GS, Fu YX, Hehlhans T, Mebius RE, van der Wall M, Kruspe D, Englert C, Lovas A, Hu D, Randolph GJ, Weih F, Habenicht AJ. Lymphotoxin β receptor signaling promotes tertiary lymphoid organogenesis in the aorta adventitia of aged ApoE^{-/-} mice. *J Exp Med*. 2009;206:233–248.
 58. Volger OL, Fledderus JO, Kisters N, Fontijn RD, Moerland PD, Kuiper J, van Berkel TJ, Bijns AP, Daemen MJ, Pannekoek H, Horrevoets AJ. Distinctive expression of chemokines and transforming growth factor- β signaling in human arterial endothelium during atherosclerosis. *Am J Pathol*. 2007;171:326–337.
 59. Trogan E, Choudhury RP, Dansky HM, Rong JX, Breslow JL, Fisher EA. Laser capture microdissection analysis of gene expression in macrophages from atherosclerotic lesions of apolipoprotein E-deficient mice. *Proc Natl Acad Sci U S A*. 2002;99:2234–2239.
 60. Kleemann R, Verschuren L, van Erk MJ, Nikolsky Y, Cnubben NH, Verheij ER, Smilde AK, Hendriks HF, Zadelaar S, Smith GJ, Kaznatcheev V, Nikolskaya T, Melnikov A, Hurt-Camejo E, van der Greef J, van Ommen B, Kooistra T. Atherosclerosis and liver inflammation induced by increased dietary cholesterol intake: a combined transcriptomics and metabolomics analysis. *Genome Biol*. 2007;8:R200.
 61. Boone LR, Lagor WR, Moya Mde L, Niesen MI, Rothblat GH, Ness GC. Thyroid hormone enhances the ability of serum to accept cellular cholesterol via the abca1 transporter. *Atherosclerosis*. 2011;218:77–82.
 62. Hagg S, Skogsberg J, Lundstrom J, Noori P, Nilsson R, Zhong H, Maleki S, Shang MM, Brinne B, Bradshaw M, Bajic VB, Samnegard A, Silveira A, Kaplan LM, Gigante B, Leander K, de Faire U, Rosfors S, Lockowandt U, Liska J, Konrad P, Takolander R, Franco-Cereceda A, Schadt EE, Ivert T, Hamsten A, Tegner J, Bjorkegren J. Multi-organ expression profiling uncovers a gene module in coronary artery disease involving transendothelial migration of leukocytes and LIM domain binding 2: the Stockholm Atherosclerosis Gene Expression (STAGE) study. *PLoS Genet*. 2009;5:e1000754.
 63. Wingrove JA, Daniels SE, Sehnert AJ, Tingley W, Elashoff MR, Rosenberg S, Buellfeld L, Grube E, Newby LK, Ginsburg GS, Kraus WE. Correlation of peripheral-blood gene expression with the extent of coronary artery stenosis. *Circ Cardiovasc Genet*. 2008;1:31–38.
 64. Sinnave PR, Donahue MP, Grass P, Seo D, Vonderscher J, Chibout SD, Kraus WE, Sketch M Jr, Nelson C, Ginsburg GS, Goldschmidt-Clermont PJ, Granger CB. Gene expression patterns in peripheral blood correlate with the extent of coronary artery disease. *PLoS One*. 2009;4:e7037.
 65. Taurino C, Miller WH, McBride MW, McClure JD, Khanin R, Moreno MU, Dymott JA, Delles C, Dominiczak AF. Gene expression profiling in whole blood of patients with coronary artery disease. *Clin Sci (Lond)*. 2010;119:335–343.
 66. Elashoff MR, Wingrove JA, Beineke P, Daniels SE, Tingley WG, Rosenberg S, Voros S, Kraus WE, Ginsburg GS, Schwartz RS, Ellis SG, Tahirkheli N, Waksman R, McPherson J, Lansky AJ, Topol EJ. Development of a blood-based gene expression algorithm for assessment of obstructive coronary artery disease in non-diabetic patients. *BMC Med Genomics*. 2011;4:26.
 67. Tsaousi A, Williams H, Lyon CA, Taylor V, Swain A, Johnson JL, George SJ. Wnt4/ β -catenin signaling induces VSMC proliferation and is associated with intimal thickening. *Circ Res*. 2011;108:427–436.
 68. Chen T, Huang Z, Wang L, Wang Y, Wu F, Meng S, Wang C. MicroRNA-125a-5p partly regulates the inflammatory response, lipid uptake, and ORP9 expression in oxLDL-stimulated monocyte/macrophages. *Cardiovasc Res*. 2009;83:131–139.
 69. Morikawa S, Takabe W, Mataka C, Wada Y, Izumi A, Saito Y, Hamakubo T, Kodama T. Global analysis of RNA expression profile in human vascular cells treated with statins. *J Atheroscler Thromb*. 2004;11:62–72.
 70. Ji R, Cheng Y, Yue J, Yang J, Liu X, Chen H, Dean DB, Zhang C. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of microRNA in vascular neointimal lesion formation. *Circ Res*. 2007;100:1579–1588.
 71. Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C, Weber M, Hamm CW, Roxe T, Muller-Ardogan M, Bonauer A, Zeiher

- AM, Dimmeler S. Circulating microRNAs in patients with coronary artery disease. *Circ Res*. 2010;107:677–684.
72. Freedman JE, Vitseva O, Tanriverdi K. The role of the blood transcriptome in innate inflammation and stroke. *Ann N Y Acad Sci*. 2010;1207:41–45.
 73. Sharp FR, Jickling GC, Stamova B, Tian Y, Zhan X, Liu D, Kuczynski B, Cox CD, Ander BP. Molecular markers and mechanisms of stroke: RNA studies of blood in animals and humans. *J Cereb Blood Flow Metab*. 2011;31:1513–1531.
 74. Liu XS, Chopp M, Zhang RL, Tao T, Wang XL, Kassis H, Hozeska-Solgot A, Zhang L, Chen C, Zhang ZG. MicroRNA profiling in subventricular zone after stroke: MiR-124a regulates proliferation of neural progenitor cells through Notch signaling pathway. *PLoS One*. 2011;6:e23461.
 75. Weng H, Shen C, Hirokawa G, Ji X, Takahashi R, Shimada K, Kishimoto C, Iwai N. Plasma miR-124 as a biomarker for cerebral infarction. *Biomed Res*. 2011;32:135–141.
 76. Chen MJ, Wong CH, Peng ZF, Manikandan J, Melendez AJ, Tan TM, Crack PJ, Cheung NS. A global transcriptomic view of the multifaceted role of glutathione peroxidase-1 in cerebral ischemic-reperfusion injury. *Free Radic Biol Med*. 2011;50:736–748.
 77. Fu S, Zhao H, Shi J, Abzhanov A, Crawford K, Ohno-Machado L, Zhou J, Du Y, Kuo WP, Zhang J, Jiang M, Jin JG. Peripheral arterial occlusive disease: global gene expression analyses suggest a major role for immune and inflammatory responses. *BMC Genomics*. 2008;9:369.
 78. Evans DC, Sileshi B, Zakaria AM, Giangiacomo D, Manson RJ, Lawson JH. Genomic modeling of atherosclerosis in peripheral arterial disease and its variant phenotype in patients with diabetes. *Vascular*. 2008;16:225–235.
 79. Prokopi M, Mayr M. Proteomics: a reality-check for putative stem cells. *Circ Res*. 2011;108:499–511.
 80. Cecchetti A, Rocchiccioli S, Boccardi C, Citti L. Vascular smooth-muscle-cell activation: proteomics point of view. *Int Rev Cell Mol Biol*. 2011;288:43–99.
 81. Janes KA, Albeck JG, Peng LX, Sorger PK, Lauffenburger DA, Yaffe MB. A high-throughput quantitative multiplex kinase assay for monitoring information flow in signaling networks: application to sepsis-apoptosis. *Mol Cell Proteomics*. 2003;2:463–473.
 82. Aebersold R, Mann M. Mass spectrometry-based proteomics. *Nature*. 2003;422:198–207.
 83. Brisset AC, Hao H, Camenzind E, Bacchetta M, Geinoz A, Sanchez JC, Chaponnier C, Gabbiani G, Bochaton-Piallat ML. Intimal smooth muscle cells of porcine and human coronary artery express S100A4, a marker of the rhomboid phenotype in vitro. *Circ Res*. 2007;100:1055–1062.
 84. Dupont A, Corseaux D, Dekeyzer O, Drobecq H, Guihot AL, Susen S, Vincentelli A, Amouyel P, Jude B, Pinet F. The proteome and secretome of human arterial smooth muscle cells. *Proteomics*. 2005;5:585–596.
 85. Mayr U, Mayr M, Yin X, Begum S, Tarelli E, Wait R, Xu Q. Proteomic dataset of mouse aortic smooth muscle cells. *Proteomics*. 2005;5:4546–4557.
 86. Bruneel A, Labas V, Mailloux A, Sharma S, Vinh J, Vaubourdolle M, Baudin B. Proteomic study of human umbilical vein endothelial cells in culture. *Proteomics*. 2003;3:714–723.
 87. Gonzalez-Cabrero J, Pozo M, Duran MC, de Nicolas R, Egido J, Vivanco F. The proteome of endothelial cells. *Methods Mol Biol*. 2007;357:181–198.
 88. Li Y, Massey K, Witkiewicz H, Schnitzer JE. Systems analysis of endothelial cell plasma membrane proteome of rat lung microvasculature. *Proteome Sci*. 2011;9:15.
 89. Bagnato C, Thumar J, Mayya V, Hwang SI, Zebroski H, Claffey KP, Haudenschild C, Eng JK, Lundgren DH, Han DK. Proteomics analysis of human coronary atherosclerotic plaque: a feasibility study of direct tissue proteomics by liquid chromatography and tandem mass spectrometry. *Mol Cell Proteomics*. 2007;6:1088–1102.
 90. Martinet W, Schrijvers DM, De Meyer GR, Herman AG, Kockx MM. Western array analysis of human atherosclerotic plaques: downregulation of apoptosis-linked gene 2. *Cardiovasc Res*. 2003;60:259–267.
 91. Mayr M, Zampetaki A, Sidibe A, Mayr U, Yin X, De Souza AI, Chung YL, Madhu B, Quax PH, Hu Y, Griffiths JR, Xu Q. Proteomic and metabolomic analysis of smooth muscle cells derived from the arterial media and adventitial progenitors of apolipoprotein E-deficient mice. *Circ Res*. 2008;102:1046–1056.
 92. Garcia-Arguinzonis M, Padro T, Lugano R, Llorente-Cortes V, Badimon L. Low-density lipoproteins induce heat shock protein 27 dephosphorylation, oligomerization, and subcellular relocalization in human vascular smooth muscle cells. *Arterioscler Thromb Vasc Biol*. 2010;30:1212–1219.
 93. Qi YX, Jiang J, Jiang XH, Wang XD, Ji SY, Han Y, Long DK, Shen BR, Yan ZQ, Chien S, Jiang ZL. PDGF-BB and TGF- β 1 on cross-talk between endothelial and smooth muscle cells in vascular remodeling induced by low shear stress. *Proc Natl Acad Sci U S A*. 2011;108:1908–1913.
 94. Zimman A, Chen SS, Komisopoulou E, Titz B, Martinez-Pinna R, Kafi A, Berliner JA, Graeber TG. Activation of aortic endothelial cells by oxidized phospholipids: a phosphoproteomic analysis. *J Proteome Res*. 2010;9:2812–2824.
 95. Zhang X, Guo T, Wang H, He W, Mei H, Hong M, Yu J, Hu Y, Song S. Potential biomarkers of acute cerebral infarction detected by SELDI-TOF-MS. *Am J Clin Pathol*. 2008;130:299–304.
 96. Koh PO. Proteomic analysis of focal cerebral ischemic injury in male rats. *J Vet Med Sci*. 2010;72:181–185.
 97. Prentice RL, Paczesny S, Aragaki A, Amon LM, Chen L, Pitteri SJ, McIntosh M, Wang P, Buson Busald T, Hsia J, Jackson RD, Rossouw JE, Manson JE, Johnson K, Eaton C, Hanash SM. Novel proteins associated with risk for coronary heart disease or stroke among postmenopausal women identified by in-depth plasma proteome profiling. *Genome Med*. 2010;2:48.
 98. Cooke JP, Wilson AM. Biomarkers of peripheral arterial disease. *J Am Coll Cardiol*. 2010;55:2017–2023.
 99. Wilson AM, Kimura E, Harada RK, Nair N, Narasimhan B, Meng XY, Zhang F, Beck KR, Olin JW, Fung ET, Cooke JP. β 2-Microglobulin as a biomarker in peripheral arterial disease: proteomic profiling and clinical studies. *Circulation*. 2007;116:1396–1403.
 100. Farley AR, Link AJ. Identification and quantification of protein post-translational modifications. *Methods Enzymol*. 2009;463:725–763.
 101. Drexler DM, Reilly MD, Shipkova PA. Advances in mass spectrometry applied to pharmaceutical metabolomics. *Anal Bioanal Chem*. 2011;399:2645–2653.
 102. Dunn WB, Broadhurst DI, Atherton HJ, Goodacre R, Griffin JL. Systems level studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy. *Chem Soc Rev*. 2011;40:387–426.
 103. Goonewardena SN, Prevette LE, Desai AA. Metabolomics and atherosclerosis. *Curr Atheroscler Rep*. 2010;12:267–272.
 104. Waterman CL, Kian-Kai C, Griffin JL. Metabolomic strategies to study lipotoxicity in cardiovascular disease. *Biochim Biophys Acta*. 2010;1801:230–234.
 105. Shah SH, Hauser ER, Bain JR, Muehlbauer MJ, Haynes C, Stevens RD, Wenner BR, Dowdy ZE, Granger CB, Ginsburg GS, Newgard CB, Kraus WE. High heritability of metabolomic profiles in families burdened with premature cardiovascular disease. *Mol Syst Biol*. 2009;5:258.
 106. Atherton HJ, Gulston MK, Bailey NJ, Cheng KK, Zhang W, Clarke K, Griffin JL. Metabolomics of the interaction between PPAR- α and age in the PPAR- α -null mouse. *Mol Syst Biol*. 2009;5:259.
 107. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, Feldstein AE, Britt EB, Fu X, Chung YM, Wu Y, Schauer P, Smith JD, Allayee H, Tang WH, DiDonato JA, Lusis AJ, Hazen SL. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. *Nature*. 2011;472:57–63.
 108. Velagapudi VR, Hezaveh R, Reigstad CS, Gopalacharyulu P, Yetukuri L, Islam S, Felin J, Perkins R, Boren J, Oresic M, Backhed F. The gut microbiota modulates host energy and lipid metabolism in mice. *J Lipid Res*. 2010;51:1101–1112.
 109. Claus SP, Ellero SL, Berger B, Krause L, Bruttin A, Molina J, Paris A, Wang EJ, de Waziers I, Cloarec O, Richards SE, Wang Y, Dumas ME, Ross A, Rezzi S, Kochhar S, Van Bladeren P, Lindon JC, Holmes E, Nicholson JK. Colonization-induced host-gut microbial metabolic interaction. *MBio*. 2011;2:e00271–e00210.
 110. Rak K, Rader DJ. Cardiovascular disease: the diet-microbe morbid union. *Nature*. 2011;472:40–41.
 111. Jung JY, Lee HS, Kang DG, Kim NS, Cha MH, Bang OS, Ryu do H, Hwang GS. 1H-NMR-based metabolomics study of cerebral infarction. *Stroke*. 2011;42:1282–1288.
 112. Sinclair AJ, Viant MR, Ball AK, Burdon MA, Walker EA, Stewart PM, Rauz S, Young SP. NMR-based metabolomic analysis of cerebrospinal fluid and serum in neurological diseases: a diagnostic tool? *NMR Biomed*. 2010;23:123–132.

113. Ekroos K, Janis M, Tarasov K, Hurme R, Laaksonen R. Lipidomics: a tool for studies of atherosclerosis. *Curr Atheroscler Rep*. 2010;12:273–281.
114. Wenk MR. Lipidomics: new tools and applications. *Cell*. 2010;143:888–895.
115. Kotronen A, Velagapudi VR, Yetukuri L, Westerbacka J, Bergholm R, Ekroos K, Makkonen J, Taskinen MR, Oresic M, Yki-Jarvinen H. Serum saturated fatty acids containing triacylglycerols are better markers of insulin resistance than total serum triacylglycerol concentrations. *Diabetologia*. 2009;52:684–690.
116. Wheelock CE, Wheelock AM, Kawashima S, Diez D, Kanehisa M, van Erk M, Kleemann R, Haegstrom JZ, Goto S. Systems biology approaches and pathway tools for investigating cardiovascular disease. *Mol Biosyst*. 2009;5:588–602.
117. Fonteh AN, Fisher RD. Combining lipidomics and proteomics of human cerebrospinal fluids. *Methods Mol Biol*. 2009;579:71–86.
118. Fonteh AN, Harrington RJ, Huhmer AF, Biringier RG, Riggins JN, Harrington MG. Identification of disease markers in human cerebrospinal fluid using lipidomic and proteomic methods. *Dis Markers*. 2006;22:39–64.
119. Chandra H, Reddy PJ, Srivastava S. Protein microarrays and novel detection platforms. *Expert Rev Proteomics*. 2011;8:61–79.
120. Katz C, Levy-Beladev L, Rotem-Bamberger S, Rito T, Rudiger SG, Friedler A. Studying protein-protein interactions using peptide arrays. *Chem Soc Rev*. 2011;40:2131–2145.
121. Huang RP. An array of possibilities in cancer research using cytokine antibody arrays. *Expert Rev Proteomics*. 2007;4:299–308.
122. Hao Q, Wang L, Tang H. Vascular endothelial growth factor induces protein kinase d-dependent production of proinflammatory cytokines in endothelial cells. *Am J Physiol Cell Physiol*. 2009;296:C821–C827.
123. Botto S, Streblow DN, DeFilippis V, White L, Kreklywich CN, Smith PP, Caposio P. IL-6 in human cytomegalovirus secretome promotes angiogenesis and survival of endothelial cells through the stimulation of survivin. *Blood*. 2011;117:352–361.
124. Sachs K, Perez O, Pe'er D, Lauffenburger DA, Nolan GP. Causal protein-signaling networks derived from multiparameter single-cell data. *Science*. 2005;308:523–529.
125. Kingsmore SF. Multiplexed protein measurement: technologies and applications of protein and antibody arrays. *Nat Rev Drug Discov*. 2006;5:310–320.
126. Mohr S, Bakal C, Perrimon N. Genomic screening with RNAi: results and challenges. *Annu Rev Biochem*. 2010;79:37–64.
127. Falschlehner C, Steinbrink S, Erdmann G, Boutros M. High-throughput RNAi screening to dissect cellular pathways: a how-to guide. *Biotechnol J*. 2010;5:368–376.
128. Mattila J, Puig O. Insights to transcriptional networks by using high throughput RNAi strategies. *Brief Funct Genomics*. 2010;9:43–52.
129. Bauch A, Superti-Furga G. Charting protein complexes, signaling pathways, and networks in the immune system. *Immunol Rev*. 2006;210:187–207.
130. Friedman A, Perrimon N. High-throughput approaches to dissecting MAPK signaling pathways. *Methods*. 2006;40:262–271.
131. Friedman A, Perrimon N. A functional RNAi screen for regulators of receptor tyrosine kinase and ERK signalling. *Nature*. 2006;444:230–234.
132. Yao Y, Shao ES, Jumabay M, Shahbazian A, Ji S, Bostrom KI. High-density lipoproteins affect endothelial BMP-signaling by modulating expression of the activin-like kinase receptor 1 and 2. *Arterioscler Thromb Vasc Biol*. 2008;28:2266–2274.
133. Sperone A, Dryden NH, Birdsey GM, Madden L, Johns M, Evans PC, Mason JC, Haskard DO, Boyle JJ, Paleolog EM, Randi AM. The transcription factor Erg inhibits vascular inflammation by repressing NF- κ B activation and proinflammatory gene expression in endothelial cells. *Arterioscler Thromb Vasc Biol*. 2011;31:142–150.
134. Tawa H, Rikitake Y, Takahashi M, Amano H, Miyata M, Satomi-Kobayashi S, Kinugasa M, Nagamatsu Y, Majima T, Ogita H, Miyoshi J, Hirata K, Takai Y. Role of afadin in vascular endothelial growth factor- and sphingosine 1-phosphate-induced angiogenesis. *Circ Res*. 2010;106:1731–1742.
135. Feng Y, Hu J, Ma J, Feng K, Zhang X, Yang S, Wang W, Zhang J, Zhang Y. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways. *Eur J Cancer*. 2011;47:2353–2363.
136. Zerneck A, Weber C. Chemokines in the vascular inflammatory response of atherosclerosis. *Cardiovasc Res*. 2010;86:192–201.
137. Zerneck A, Bidzhekov K, Noels H, Shagdarsuren E, Gan L, Denecke B, Hristov M, Koppel T, Jahantigh MN, Lutgens E, Wang S, Olson EN, Schober A, Weber C. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. *Sci Signal*. 2009;2:ra81.
138. Bartz F, Kern L, Erz D, Zhu M, Gilbert D, Meinhof T, Wirkner U, Erfle H, Muckenthaler M, Pepperkok R, Runz H. Identification of cholesterol-regulating genes by targeted RNAi screening. *Cell Metab*. 2009;10:63–75.
139. Arora S, Beaudry C, Bisanz KM, Sima C, Kiefer JA, Azorsa DO. A high-content RNAi-screening assay to identify modulators of cholesterol accumulation in Niemann-Pick type C cells. *Assay Drug Dev Technol*. 2010;8:295–320.
140. Yin KJ, Deng Z, Hamblin M, Zhang J, Chen YE. Vascular PPAR δ protects against stroke-induced brain injury. *Arterioscler Thromb Vasc Biol*. 2011;31:574–581.
141. Al-Jamal KT, Gherardini L, Bardi G, Nunes A, Guo C, Bussy C, Herrero MA, Bianco A, Prato M, Kostarelos K, Pizzorusso T. Functional motor recovery from brain ischemic insult by carbon nanotube-mediated siRNA silencing. *Proc Natl Acad Sci U S A*. 2011;108:10952–10957.
142. Smadja DM, d'Audigier C, Bieche I, Evrard S, Mauge L, Dias JV, Labreuche J, Laurendeau I, Marsac B, Dizier B, Wagner-Ballon O, Boisson-Vidal C, Morandi V, Duong-Van-Huyen JP, Bruneval P, Dignat-George F, Emmerich J, Gaussem P. Thrombospondin-1 is a plasmatic marker of peripheral arterial disease that modulates endothelial progenitor cell angiogenic properties. *Arterioscler Thromb Vasc Biol*. 2011;31:551–559.
143. Kaikkonen MU, Lam MT, Glass CK. Non-coding RNAs as regulators of gene expression and epigenetics. *Cardiovasc Res*. 2011;90:430–440.
144. Moving ahead with an international human epigenome project. *Nature*. 2008;454:711–715.
145. Cokus SJ, Feng S, Zhang X, Chen Z, Merriman B, Haudenschild CD, Pradhan S, Nelson SF, Pellegrini M, Jacobsen SE. Shotgun bisulphite sequencing of the arabidopsis genome reveals DNA methylation patterning. *Nature*. 2008;452:215–219.
146. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, Wei G, Chepelev I, Zhao K. High-resolution profiling of histone methylations in the human genome. *Cell*. 2007;129:823–837.
147. Mikkelsen TS, Ku M, Jaffe DB, Issac B, Lieberman E, Giannoukos G, Alvarez P, Brockman W, Kim TK, Koche RP, Lee W, Mendenhall E, O'Donovan A, Presser A, Russ C, Xie X, Meissner A, Wernig M, Jaenisch R, Nusbaum C, Lander ES, Bernstein BE. Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. *Nature*. 2007;448:553–560.
148. van Straten EM, Bloks VW, Huijman NC, Baller JF, van Meer H, Lutjohann D, Kuipers F, Plosch T. The liver X-receptor gene promoter is hypermethylated in a mouse model of prenatal protein restriction. *Am J Physiol Regul Integr Comp Physiol*. 2010;298:R275–R282.
149. Bibikova M, Lin Z, Zhou L, Chudin E, Garcia EW, Wu B, Doucet D, Thomas NJ, Wang Y, Vollmer E, Goldmann T, Seifart C, Jiang W, Barker DL, Chee MS, Floros J, Fan JB. High-throughput DNA methylation profiling using universal bead arrays. *Genome Res*. 2006;16:383–393.
150. Ehrich M, Nelson MR, Stanssens P, Zabeau M, Liloglou T, Xinarianos G, Cantor CR, Field JK, van den Boom D. Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. *Proc Natl Acad Sci U S A*. 2005;102:15785–15790.
151. Baccarelli A, Wright R, Bollati V, Litonjua A, Zanobetti A, Tarantini L, Sparrow D, Vokonas P, Schwartz J. Ischemic heart disease and stroke in relation to blood DNA methylation. *Epidemiology*. 2010;21:819–828.
152. Kim M, Long TI, Arakawa K, Wang R, Yu MC, Laird PW. DNA methylation as a biomarker for cardiovascular disease risk. *PLoS One*. 2010;5:e9692.
153. Ordovas JM, Smith CE. Epigenetics and cardiovascular disease. *Nat Rev Cardiol*. 2010;7:510–519.
154. Endres M, Meisel A, Biniszkiwicz D, Namura S, Prass K, Ruscher K, Lipski A, Jaenisch R, Moskowitz MA, Dirnagl U. DNA methyltransferase contributes to delayed ischemic brain injury. *J Neurosci*. 2000;20:3175–3181.
155. Qureshi IA, Mehler MF. Emerging role of epigenetics in stroke: part 1: DNA methylation and chromatin modifications. *Arch Neurol*. 2010;67:1316–1322.

156. Alkemade FE, van Vliet P, Henneman P, van Dijk KW, Hierck BP, van Munsteren JC, Scheerman JA, Goeman JJ, Havekes LM, Gittenberger-de Groot AC, van den Elsen PJ, DeRuiter MC. Prenatal exposure to apoE deficiency and postnatal hypercholesterolemia are associated with altered cell-specific lysine methyltransferase and histone methylation patterns in the vasculature. *Am J Pathol.* 2010;176:542–548.
157. Dje N, Guesson P, Riediger F, Vardarova K, Scharf S, Eitel J, Opitz B, Slevogt H, Weichert W, Hocke AC, Schmeck B, Suttorp N, Hippenstiel S. Statins control oxidized LDL-mediated histone modifications and gene expression in cultured human endothelial cells. *Arterioscler Thromb Vasc Biol.* 2009;29:380–386.
158. Turunen MP, Aavik E, Yla-Herttuala S. Epigenetics and atherosclerosis. *Biochim Biophys Acta.* 2009;1790:886–891.
159. Baccarelli A, Rienstra M, Benjamin EJ. Cardiovascular epigenetics: basic concepts and results from animal and human studies. *Circ Cardiovasc Genet.* 2010;3:567–573.
160. Breton CV, Byun HM, Wenten M, Pan F, Yang A, Gilliland FD. Prenatal tobacco smoke exposure affects global and gene-specific DNA methylation. *Am J Respir Crit Care Med.* 2009;180:462–467.
161. Breitling LP, Yang R, Korn B, Burwinkel B, Brenner H. Tobacco-smoking-related differential DNA methylation: 27K discovery and replication. *Am J Hum Genet.* 2011;88:450–457.
162. Movassagh M, Choy MK, Goddard M, Bennett MR, Down TA, Foo RS. Differential DNA methylation correlates with differential expression of angiogenic factors in human heart failure. *PLoS One.* 2010;5:e8564.
163. Bressler J, Shimmin LC, Boerwinkle E, Hixson JE. Global DNA methylation and risk of subclinical atherosclerosis in young adults: the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study. *Atherosclerosis.* 2011;219:958–962.
164. Ramsey SA, Gold ES, Aderem A. A systems biology approach to understanding atherosclerosis. *EMBO Mol Med.* 2010;2:79–89.
165. Lusis AJ, Weiss JN. Cardiovascular networks: systems-based approaches to cardiovascular disease. *Circulation.* 2010;121:157–170.
166. Diez D, Wheelock AM, Goto S, Haeggstrom JZ, Paulsson-Berne G, Hansson GK, Hedin U, Gabrielsen A, Wheelock CE. The use of network analyses for elucidating mechanisms in cardiovascular disease. *Mol Biosyst.* 2010;6:289–304.
167. Torkamani A, Topol EJ, Schork NJ. Pathway analysis of seven common diseases assessed by genome-wide association. *Genomics.* 2008;92:265–272.
168. Gilchrist M, Thorsson V, Li B, Rust AG, Korb M, Roach JC, Kennedy K, Hai T, Bolouri H, Aderem A. Systems biology approaches identify ATF3 as a negative regulator of Toll-like receptor 4. *Nature.* 2006;441:173–178.
169. Ramsey SA, Klemm SL, Zak DE, Kennedy KA, Thorsson V, Li B, Gilchrist M, Gold ES, Johnson CD, Litvak V, Navarro G, Roach JC, Rosenberger CM, Rust AG, Yudkovsky N, Aderem A, Shmulevich I. Uncovering a macrophage transcriptional program by integrating evidence from motif scanning and expression dynamics. *PLoS Comput Biol.* 2008;4:e1000021.
170. Tseng HW, Juan HF, Huang HC, Lin JY, Sinchaikul S, Lai TC, Chen CF, Chen ST, Wang GJ. Lipopolysaccharide-stimulated responses in rat aortic endothelial cells by a systems biology approach. *Proteomics.* 2006;6:5915–5928.
171. Langfelder P, Castellani LW, Zhou Z, Paul E, Davis R, Schadt EE, Lusis AJ, Horvath S, Mehrabian M. A systems genetic analysis of high density lipoprotein metabolism and network preservation across mouse models. *Biochim Biophys Acta.* 2011.
172. Gargalovic PS, Imura M, Zhang B, Gharavi NM, Clark MJ, Pagnon J, Yang WP, He A, Truong A, Patel S, Nelson SF, Horvath S, Berliner JA, Kirchgessner TG, Lusis AJ. Identification of inflammatory gene modules based on variations of human endothelial cell responses to oxidized lipids. *Proc Natl Acad Sci U S A.* 2006;103:12741–12746.
173. Mac Gabhann F, Qutub AA, Annex BH, Popel AS. Systems biology of pro-angiogenic therapies targeting the VEGF system. *Wiley Interdiscip Rev Syst Biol Med.* 2010;2:694–707.
174. McDermott JE, Archuleta M, Stevens SL, Stenzel-Poore MP, Sanfilippo A. Defining the players in higher-order networks: predictive modeling for reverse engineering functional influence networks. *Pac Symp Biocomput.* 2011:314–325.
175. Joyce AR, Paulsson BO. The model organism as a system: integrating “omics” data sets. *Nat Rev Mol Cell Biol.* 2006;7:198–210.

Arteriosclerosis, Thrombosis, and Vascular Biology



JOURNAL OF THE AMERICAN HEART ASSOCIATION

The Use of High-Throughput Technologies to Investigate Vascular Inflammation and Atherosclerosis

Yvonne Döring, Heidi Noels and Christian Weber

Arterioscler Thromb Vasc Biol. 2012;32:182-195

doi: 10.1161/ATVBAHA.111.232686

Arteriosclerosis, Thrombosis, and Vascular Biology is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231

Copyright © 2012 American Heart Association, Inc. All rights reserved.

Print ISSN: 1079-5642. Online ISSN: 1524-4636

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://atvb.ahajournals.org/content/32/2/182>

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Arteriosclerosis, Thrombosis, and Vascular Biology* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the [Permissions and Rights Question and Answer](#) document.

Reprints: Information about reprints can be found online at:

<http://www.lww.com/reprints>

Subscriptions: Information about subscribing to *Arteriosclerosis, Thrombosis, and Vascular Biology* is online at:

<http://atvb.ahajournals.org/subscriptions/>